{"id":"W1990194653","doi":"10.1016/j.gtc.2010.08.018","title":"Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology","year":2010,"lang":"en","type":"review","venue":"Gastroenterology Clinics of North America","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration","keywords":"Medicine; Certolizumab pegol; Infliximab; Adalimumab; Inflammatory bowel disease; Ulcerative colitis; Vedolizumab; Monoclonal antibody; Tumor necrosis factor alpha; Crohn's disease; Immunology; Disease; Psoriasis; Antibody; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005394402,0.0007032652,0.001928765,0.0001899978,0.00006540069,0.00001118993,0.001040455,0.0004056104,0.00002991568],"category_scores_gemma":[0.0006326323,0.0005284803,0.001521814,0.0001178236,0.001493969,0.00001384792,0.0002201482,0.0007223348,0.00001822768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003322662,"about_ca_system_score_gemma":0.0008197488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009515742,"about_ca_topic_score_gemma":0.0001137145,"domain_scores_codex":[0.9936208,0.001976257,0.002589656,0.0008860375,0.0002894437,0.000637881],"domain_scores_gemma":[0.9947792,0.0006751915,0.002837589,0.001181643,0.0002583682,0.0002680486],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004360175,0.004157394,0.6481603,0.002307324,0.001526277,0.0007830148,0.0001003004,0.00002669046,0.000006800055,0.000002707322,0.001138506,0.3374304],"study_design_scores_gemma":[0.001307044,0.002180521,0.2405211,0.0001607002,0.001532271,0.00003492267,0.0000190727,0.00000896438,0.000001144727,0.000002216065,0.7539932,0.000238821],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.5594336,0.4369072,0.00001888504,0.000082439,0.0009319762,0.001340932,0.001252037,0.0000119375,0.00002097525],"genre_scores_gemma":[0.005128905,0.9915314,0.0006485555,0.0008645083,0.0005657729,0.0002814793,0.000889989,0.00007088412,0.0000185587],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.7528546,"threshold_uncertainty_score":0.9997167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02603943426879796,"score_gpt":0.3666919273421982,"score_spread":0.3406524930734003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}